High-density Lipoproteins and Apolipoprotein A-I: Potential New Players in the Prevention and Treatment of Lung Disease
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Apolipoprotein A-I (apoA-I) and high-density lipoproteins (HDL) mediate reverse cholesterol transport out of cells. Furthermore, HDL has additional protective functions, which include anti-oxidative, anti-inflammatory, anti-apoptotic, and vasoprotective effects. In contrast, HDL can become dysfunctional with a reduction in both cholesterol efflux and anti-inflammatory properties in the setting of disease or the acute phase response. These paradigms are increasingly being recognized to be active in the pulmonary system, where apoA-I and HDL have protective effects in normal lung health, as well as in a variety of disease states, including acute lung injury (ALI), asthma, chronic obstructive pulmonary disease, lung cancer, pulmonary arterial hypertension, pulmonary fibrosis, and viral pneumonia. Similar to observations in cardiovascular disease, however, HDL may become dysfunctional and contribute to disease pathogenesis in respiratory disorders. Furthermore, synthetic apoA-I mimetic peptides have been shown to have protective effects in animal models of ALI, asthma, pulmonary hypertension, and influenza pneumonia. These findings provide evidence to support the concept that apoA-I mimetic peptides might be developed into a new treatment that can either prevent or attenuate the manifestations of lung diseases, such as asthma. Thus, the lung is positioned to take a page from the cardiovascular disease playbook and utilize the protective properties of HDL and apoA-I as a novel therapeutic approach.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bellani, G., Laffey, J. G., Pham, T., Fan, E., Brochard, L., Esteban, A., Gattinoni, L., van Haren, F., Larsson, A., McAuley, D. F., et al. (2016) · JAMA · doi:10.1001/jama.2016.0291 · Cited by 5,766
Raghu, G., Rochwerg, B., Zhang, Y., Garcia, C. A. C., Azuma, A., Behr, J., Brozek, J. L., Collard, H. R., Cunningham, W., Homma, S., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201506-1063st · Cited by 1,916
HDL and cardiovascular disease
Rader, D. J., & Hovingh, G. K. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61217-4 · Cited by 870
Dysfunctional HDL and atherosclerotic cardiovascular disease
Rosenson, R. S., Brewer, H. B., Ansell, B. J., Barter, P., Chapman, M. J., Heinecke, J. W., Kontush, A., Tall, A. R., & Webb, N. R. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.124 · Cited by 822
Mora, S., Otvos, J. D., Rifai, N., Rosenson, R. S., Buring, J. E., & Ridker, P. M. (2009) · Circulation · doi:10.1161/circulationaha.108.816181 · Cited by 490
Wurfel, M. M., Kunitake, S. T., Lichenstein, H., Kane, J. P., & Wright, S. D. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.3.1025 · Cited by 442
HDL-targeted therapies: progress, failures and future
Kingwell, B. A., Chapman, M. J., Kontush, A., & Miller, N. E. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4279 · Cited by 354
Research works printed but not linked: 56
- Barochia, 2016, Serum high density lipoprotein cholesterol and large HDL particles are negatively correlated with blood eosinophils in atopic asthma., Am. J. Resp. Crit. Care Med., 193
- Barochia, 2015, Serum apolipoprotein A-I and large high-density lipoprotein particles are positively correlated with FEV1 in atopic asthma., Am. J. Resp. Crit. Care Med., 191, 990, 10.1164/rccm.201411-1990OC · DOI
- Bates, 2005, Pulmonary abnormalities due to abca1 deficiency in mice., Am. J. Physiol. Lung Cell Mol. Physiol., 289, L980, 10.1152/ajplung.00234.2005 · DOI
- Bates, 2008, Expression and biological activity of ABCA1 in alveolar epithelial cells., Am. J. Respir. Cell Mol. Biol., 38, 283, 10.1165/rcmb.2007-0020OC · DOI
- Bloedon, 2008, Safety, pharmacokinetics, and pharmacodynamics of oral apoa-i mimetic peptide D-4F in high-risk cardiovascular patients., J. Lipid Res., 49, 1344, 10.1194/jlr.P800003-JLR200 · DOI · Paper page
- Bortnick, 2003, Identification and characterization of rodent ABCA1 in isolated type II pneumocytes., Am. J. Physiol. Lung Cell Mol. Physiol., 285, L869, 10.1152/ajplung.00077.2003 · DOI
- Burkart, 2014, ApoM and high-density lipoprotein cholesterol are associated with lung function and per cent emphysema., Eur. Respir. J., 43, 1003, 10.1183/09031936.00147612 · DOI
- Catapano, 2014, HDL in innate and adaptive immunity., Cardiovasc. Res., 103, 372, 10.1093/cvr/cvu150 · DOI · Paper page
- Celli, 2015, An official american thoracic society/european respiratory society statement: research questions in chronic obstructive pulmonary disease., Am. J. Respir. Crit. Care Med., 191, e4, 10.1164/rccm.201501-0044ST · DOI · Paper page
- Chandler, 2016, Lipid biomarkers and long-term risk of cancer in the women’s health study., Am. J. Clin. Nutr., 103, 1397, 10.3945/ajcn.115.124321 · DOI · Paper page
- Chi, 2014, High-density lipoprotein cholesterol is a favorable prognostic factor and negatively correlated with c-reactive protein level in non-small cell lung carcinoma., PLoS ONE, 9, 10.1371/journal.pone.0091080 · DOI
- Cirillo, 2002, Lipids and pulmonary function in the third national health and nutrition examination survey., Am. J. Epidemiol., 155, 842, 10.1093/aje/155.9.842 · DOI
- Cote, 2011, Apolipoprotein A-I, A-II, and H mRNA and protein accumulation sites in the developing lung in late gestation., BMC Res. Notes, 4, 10.1186/1756-0500-4-235 · doi:10.1186/1756-0500-4-235
- Dai, 2012, Apolipoprotein A-I attenuates ovalbumin-induced neutrophilic airway inflammation via a granulocyte colony-stimulating factor-dependent mechanism., Am. J. Respir. Cell Mol. Biol., 47, 186, 10.1165/rcmb.2011-0322OC · DOI
- Dai, 2014, ATP-binding cassette transporter 1 attenuates ovalbumin-induced neutrophilic airway inflammation., Am. J. Respir. Cell Mo.l Biol., 51, 626, 10.1165/rcmb.2013-0264OC · DOI
- Delvecchio, 2008, LXR-induced reverse cholesterol transport in human airway smooth muscle is mediated exclusively by ABCA1., Am. J. Physiol. Lung. Cell Mol. Physiol., 295, L949, 10.1152/ajplung.90394.2008 · DOI
- Dunbar, 2007, Daily oral administration of the apolipoprotein A-I mimetic peptide D-4F in patients with heart disease or equivalent risk improves high-density lipoprotein anti-inflammatory function (abstract)., J. Am. Coll. Cardiol., 49
- Emancipator, 1992, In vitro inactivation of bacterial endotoxin by human lipoproteins and apolipoproteins., Infect. Immun., 60, 596, 10.1128/IAI.60.2.596-601.1992 · DOI · Paper page
- Hao, 2014, Haplotype analysis of apoAI gene and sepsis-associated acute lung injury., Lipids Health Dis., 13, 10.1186/1476-511X-13-79 · DOI
- Henning, 2011, Contribution of the c-terminal end of apolipoprotein AI to neutralization of lipopolysaccharide endotoxic effect., Innate Immun., 17, 327, 10.1177/1753425910370709 · DOI
- Heresi, 2010, Plasma levels of high-density lipoprotein cholesterol and outcomes in pulmonary arterial hypertension., Am. J. Respir. Crit. Care Med., 182, 661, 10.1164/rccm.201001-0007OC · DOI
- Jiao, 2008, Apolipoprotein A-I diminishes acute lung injury and sepsis in mice induced by lipoteichoic acid., Cytokine, 43, 83, 10.1016/j.cyto.2008.04.002 · DOI
- Kim, 2016, Attenuation of cigarette smoke-induced emphysema in mice by apolipoprotein A-1 overexpression., Am. J. Respir. Cell Mol. Biol., 54, 91, 10.1165/rcmb.2014-0305OC · DOI
- Kim, 2010, Role of lung apolipoprotein A-I in idiopathic pulmonary fibrosis: antiinflammatory and antifibrotic effect on experimental lung injury and fibrosis., Am. J. Respir. Crit. Care Med., 182, 633, 10.1164/rccm.200905-0659OC · DOI · Paper page
- Kucharska-Newton, 2008, HDL-cholesterol and the incidence of lung cancer in the atherosclerosis risk in communities (ARIC) study., Lung Cancer, 61, 292, 10.1016/j.lungcan.2008.01.015 · DOI
- Kwon, 2012, 4F, apolipoprotein AI mimetic peptide, attenuates acute lung injury and improves survival in endotoxemic rats., J. Trauma Acute Care Surg., 72, 1576, 10.1097/TA.0b013e3182493ab4 · DOI
- Lee, 2013, Overexpression of apolipoprotein A1 in the lung abrogates fibrosis in experimental silicosis., PLoS ONE, 8, 10.1371/journal.pone.0055827 · DOI
- Li, 2008, Human apoA-I overexpression diminishes LPS-induced systemic inflammation and multiple organ damage in mice., Eur. J. Pharmacol., 590, 417, 10.1016/j.ejphar.2008.06.047 · DOI
- Ma, 2004, Role of apolipoprotein A-I in protecting against endotoxin toxicity., Acta Biochim. Biophys. Sin., 36, 419, 10.1093/abbs/36.6.419 · DOI
- Madenspacher, 2012, Apolipoproteins and apolipoprotein mimetic peptides modulate phagocyte trafficking through chemotactic activity., J. Biol. Chem., 287, 43730, 10.1074/jbc.M112.377192 · DOI
- Matute-Bello, 1997, Neutrophil apoptosis in the acute respiratory distress syndrome., Am. J. Respir. Crit. Care Med., 156, 1969, 10.1164/ajrccm.156.6.96-12081 · DOI · Paper page
- McNeish, 2000, High density lipoprotein deficiency and foam cell accumulation in mice with targeted disruption of ATP-binding cassette transporter-1., Proc. Natl. Acad. Sci. U.S.A., 97, 4245, 10.1073/pnas.97.8.4245 · DOI · Paper page
- Mora, 2010, Lipoprotein particle size and concentration by nuclear magnetic resonance and incident type 2 diabetes in women., Diabetes, 59, 1153, 10.2337/db09-1114 · DOI · Paper page
- Moreno, 2014, High-density lipoproteins potentiate alpha1-antitrypsin therapy in elastase-induced pulmonary emphysema., Am. J. Respir. Cell Mol. Biol., 51, 536, 10.1165/rcmb.2013-0103OC · DOI
- Nandedkar, 2011, D-4F, an apoA-1 mimetic, decreases airway hyperresponsiveness, inflammation, and oxidative stress in a murine model of asthma., J. Lipid Res., 52, 499, 10.1194/jlr.M012724 · DOI
- Navab, 2011, HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms., Nat. Rev. Cardiol., 8, 222, 10.1038/nrcardio.2010.222 · DOI · Paper page
- Nicholas, 2010, Identification of lipocalin and apolipoprotein A1 as biomarkers of chronic obstructive pulmonary disease., Am. J. Respir. Crit. Care Med., 181, 1049, 10.1164/rccm.200906-0857OC · DOI · Paper page
- Ortiz-Munoz, 2009, HDL antielastase activity prevents smooth muscle cell anoikis, a potential new antiatherogenic property., FASEB J., 23, 3129, 10.1096/fj.08-127928 · DOI
- Park, 2013, Apolipoprotein a1 potentiates lipoxin a4 synthesis and recovery of allergen-induced disrupted tight junctions in the airway epithelium., Clin. Exp. Allergy, 43, 914, 10.1111/cea.12143 · DOI
- Provost, 2009, Apolipoprotein A-I, A-II, C-II, and H expression in the developing lung and sex difference in surfactant lipids., J. Endocrinol., 200, 321, 10.1677/JOE-08-0238 · DOI
- Rastogi, 2015, Inflammation, metabolic dysregulation, and pulmonary function among obese urban adolescents with asthma., Am. J. Respir. Crit. Care Med., 191, 149, 10.1164/rccm.201409-1587OC · DOI · Paper page
- Ross, 2015, Proinflammatory high-density lipoprotein results from oxidized lipid mediators in the pathogenesis of both idiopathic and associated types of pulmonary arterial hypertension., Pulm. Circ., 5, 640, 10.1086/683695 · DOI
- Sharifov, 2013, Anti-inflammatory mechanisms of apolipoprotein A-I mimetic peptide in acute respiratory distress syndrome secondary to sepsis., PLoS ONE, 8, 10.1371/journal.pone.0064486 · DOI
- Sharma, 2014, Apolipoprotein A-I mimetic peptide 4F rescues pulmonary hypertension by inducing microrna-193-3p., Circulation, 130, 776, 10.1161/CIRCULATIONAHA.114.007405 · doi:10.1161/circulationaha.114.007405
- Smith, 1992, Polymorphism in the human apolipoprotein A-I gene promoter region. Association of the minor allele with decreased production rate in vivo and promoter activity in vitro., J. Clin. Invest., 89, 1796, 10.1172/JCI115783 · DOI
- Tu, 2013, Association of apolipoprotein a1 -75 G/A polymorphism with susceptibility to the development of acute lung injury after cardiopulmonary bypass surgery., Lipids Health Dis., 12, 10.1186/1476-511X-12-172 · doi:10.1186/1476-511x-12-172
- Van Lenten, 2002, Influenza infection promotes macrophage traffic into arteries of mice that is prevented by D-4F, an apolipoprotein A-I mimetic peptide., Circulation, 106, 1127, 10.1161/01.CIR.0000030182.35880.3E · DOI · Paper page
- Van Lenten, 2004, D-4F, an apolipoprotein a-I mimetic peptide, inhibits the inflammatory response induced by influenza A infection of human type II pneumocytes., Circulation, 110, 3252, 10.1161/01.CIR.0000147232.75456.B3 · DOI · Paper page
- Van Lenten, 2001, High-density lipoprotein loses its anti-inflammatory properties during acute influenza A infection., Circulation, 103, 2283, 10.1161/01.CIR.103.18.2283 · DOI · Paper page
- Van Linthout, 2011, Down-regulation of endothelial TLR4 signalling after apo A-I gene transfer contributes to improved survival in an experimental model of lipopolysaccharide-induced inflammation., J. Mol. Med., 89, 151, 10.1007/s00109-010-0690-6 · DOI
- Wang, 2010, Genetic deletion of apolipoprotein a-i increases airway hyperresponsiveness, inflammation, and collagen deposition in the lung., J. Lipid Res., 51, 2560, 10.1194/jlr.M004549 · DOI
- Watson, 2011, Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function., J. Lipid Res., 52, 361, 10.1194/jlr.M011098 · DOI · Paper page
- Xiao, 2008, High-density lipoprotein attenuates lipopolysaccharide-induced acute lung injury in mice., Sheng Li Xue Bao, 60, 403
- Yan, 2006, Beneficial effects of apoA-I on LPS-induced acute lung injury and endotoxemia in mice., Life Sci., 79, 210, 10.1016/j.lfs.2006.02.011 · DOI
- Yao, 2011, 5A, an apolipoprotein A-I mimetic peptide, attenuates the induction of house dust mite-induced asthma., J. Immunol., 186, 576, 10.4049/jimmunol.1001534 · DOI · Paper page
- Zamanian-Daryoush, 2013, The cardioprotective protein apolipoprotein A1 promotes potent anti-tumorigenic effects., J. Biol. Chem., 288, 21237, 10.1074/jbc.M113.468967 · DOI · Paper page
Cited by
High-density lipoprotein revisited: biological functions and clinical relevance
von Eckardstein, A., Nordestgaard, B. G., Remaley, A. T., & Catapano, A. L. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehac605 · Cited by 401
“For example, the targeted knock-out of ABCA1 and ABCG1 in retinal pigment epithelium led to retinal degeneration in mice as seen in human AMD.(139) As interference with LDL metabolism in the liver for example by PCSK9 inhibition does not affect brain function, interference with HDL metabolism in the periphery may have…”
BackgroundResultInfluentialBurggren, A. C., Shirazi, A., Ginder, N., & London, E. D. (2019) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2019.1634086 · Cited by 144
(2018) · Europe PMC (PubMed Central) · Cited by 17
Metadata
- Authors
- Gordon, E. M., Figueroa, D. M., Barochia, A. V., Yao, X., & Levine, S. J.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2016-09-21
- Volume
- 7
- Pages
- 323-323
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W2522121027
- Cited by
- 108
- References
- 7
- FWCI
- 13.61
- Type
- journal article
- Language
- en
- Open access
- gold
- Funders
- National Heart, Lung, and Blood Institute (1 ZIA HL006053 06, 1 ZIA HL006054 06)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.